THU0272 Diagnostic Performance and Disease Activity Assessment by FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 295.1-295 ◽  
Author(s):  
M. Soussan ◽  
P. Nicolas ◽  
C. Schramm ◽  
S. Katsahian ◽  
O. Fain ◽  
...  
Keyword(s):  
Literature Review ◽  
Disease Activity ◽  
Systematic Literature Review ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Meta Analysis ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Activity Assessment ◽  
Disease Activity Assessment

scholarly journals Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12

2015 ◽  
Vol 42 (12) ◽  
pp. 2465-2469 ◽  
Author(s):  
Sibel Zehra Aydin ◽  
Haner Direskeneli ◽  
Antoine Sreih ◽  
Fatma Alibaz-Oner ◽  
Ahmet Gul ◽  
...  
Keyword(s):  
Disease Activity ◽  
Outcome Measures ◽  
Research Agenda ◽  
Task Force ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Disease Assessment ◽  
Activity Assessment ◽  
Delphi Exercise ◽  
Disease Activity Assessment

Objective.The rarity of large vessel vasculitis (LVV) is a major factor limiting randomized controlled trials in LVV, resulting in treatment choices in these diseases that are guided mainly by observational studies and expert opinion. Further complicating trials in LVV is the absence of validated and meaningful outcome measures. The Outcome Measures in Rheumatology (OMERACT) vasculitis working group initiated the Large Vessel Vasculitis task force in 2009 to develop data-driven, validated outcome tools for clinical investigation in LVV. This report summarizes the progress that has been made on a disease activity assessment tool and patient-reported outcomes in LVV as well as the group’s research agenda.Methods.The OMERACT LVV task force brought an international group of investigators and patient research partners together to work collaboratively on developing outcome tools. The group initially focused on disease activity assessment tools in LVV. Following a systematic literature review, an international Delphi exercise was conducted to obtain expert opinion on principles and domains for disease assessment. The OMERACT vasculitis working group’s LVV task force is also conducting qualitative research with patients, including interviews, focus groups, and engaging patients as research partners, all to ensure that the approach to disease assessment includes measures of patients’ perspectives and that patients have input into the research agenda and process.Results.The preliminary results of both the Delphi exercise and the qualitative interviews were discussed at the OMERACT 12 (2014) meeting and the completion of the analyses will produce an initial set of domains and instruments to form the basis of next steps in the research agenda.Conclusion.The research agenda continues to evolve, with the ultimate goal of developing an OMERACT-endorsed core set of outcome measures for use in clinical trials of LVV.

F-18 FDG PET for assessment of disease activity of large vessel vasculitis: A systematic review and meta-analysis

2018 ◽  
Vol 26 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Sang-Woo Lee ◽  
Seong-Jang Kim ◽  
Youngduk Seo ◽  
Shin Young Jeong ◽  
Byeong-Cheol Ahn ◽  
...  
Keyword(s):  
Systematic Review ◽  
Disease Activity ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Assessment Of Disease Activity

scholarly journals Disease activity assessment in large vessel vasculitis

Reumatismo ◽  
2011 ◽  
Vol 63 (2) ◽  
Author(s):  
L. Magnani ◽  
A. Versari ◽  
D. Salvo ◽  
M. Casali ◽  
G. Germanò ◽  
...  
Keyword(s):  
Disease Activity ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Activity Assessment ◽  
Disease Activity Assessment

scholarly journals Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations

RMD Open ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. e000612 ◽  
Author(s):  
Christina Duftner ◽  
Christian Dejaco ◽  
Alexandre Sepriano ◽  
Louise Falzon ◽  
Wolfgang Andreas Schmidt ◽  
...  
Keyword(s):  
Literature Review ◽  
Systematic Literature Review ◽  
Outcome Prediction ◽  
Meta Analysis ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Eular Recommendations

scholarly journals Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise

2017 ◽  
Vol 44 (12) ◽  
pp. 1928-1932 ◽  
Author(s):  
Sibel Z. Aydin ◽  
Haner Direskeneli ◽  
Peter A. Merkel ◽  
Keyword(s):  
Disease Activity ◽  
Morning Stiffness ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Clinical Activity ◽  
Activity Assessment ◽  
Core Set ◽  
Delphi Exercise ◽  
International Experts ◽  
Disease Activity Assessment

Objective.To arrive at consensus for candidate outcomes for disease activity assessment in large-vessel vasculitis (LVV) in clinical trials.Methods.A Delphi survey including 99 items was circulated among international experts for 3 rounds.Results.Fifty-seven items were accepted for both giant cell arteritis and Takayasu arteritis. Sixty-seven percent of experts voted to have a common approach for both diseases with additional disease-specific items such as weight loss, scalp tenderness/necrosis, morning stiffness, dizziness, visual symptoms, and imaging.Conclusion.This study highlights similarities and differences in experts’ perspectives for assessing clinical activity in LVV and may guide a consensus-driven core set of validated outcomes.

Diagnostic performance of FDG PET in large vessel vasculitis

2019 ◽  
Vol 7 (6) ◽  
pp. 415-425
Author(s):  
L. Leccisotti ◽  
M. Lorusso ◽  
V. Feudo ◽  
E. Gremese ◽  
A. Giordano
Keyword(s):  
Fdg Pet ◽  
Diagnostic Performance ◽  
Large Vessel Vasculitis ◽  
Large Vessel

scholarly journals Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis

Rheumatology ◽  
2020 ◽  
Vol 59 (8) ◽  
pp. 1818-1825 ◽  
Author(s):  
Benjamin Hagège ◽  
Elina Tan ◽  
Martine Gayraud ◽  
Bruno Fautrel ◽  
Laure Gossec ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Literature Review ◽  
Disease Activity ◽  
Systematic Literature Review ◽  
Activity Index ◽  
Meta Analysis ◽  
Random Effect ◽  
Disease Activity Index ◽  
Low Disease Activity ◽  
Pooled Prevalence

Abstract Objectives Remission (REM) or low disease activity (LDA) is the treatment target in psoriatic arthritis (PsA). The objective of this study was to assess the reporting and prevalence of REM/LDA in published studies of PsA. Methods This was a systematic literature review of all clinical papers published in PubMed, EMBASE or Cochrane database in English between 2012 and 2019 in the field of PsA. Data were collected regarding reporting of REM/LDA by very low disease activity/minimal disease activity (VLDA/MDA), Disease Activity index for Psoriatic Arthritis (DAPSA), or Disease Activity Score 28 joints (DAS28). The pooled rates of REM and LDA by each definition were calculated by random effect meta-analysis. Results In all, 258 publications (corresponding to 114 651 patients), of which 81 (31%) were randomized controlled trials, were analysed: patients’ mean age was 49.4 ( 4.4) years; with a mean disease duration of 8.5 ( 3.8) years. REM/LDA was reported in 91/258 (35.3%) publications. VLDA/MDA was used in 61/91 (67.0%) studies, DAPSA in 27/91 (29.6%) and DAS28 in 28/91 (30.7%), with 40/91 (43.9%) papers reporting several of these definitions. The pooled prevalence (lower–upper limits) of REM was 13.1% (10.9–15.4), 23.1% (16.8–30.1) and 42.1% (33.9–50.4) using VLDA, DAPSA-REM and DAS28, respectively. For LDA the pooled prevalence was 36.3% (32.3–40.5), 52.8% (41.8–63.6) and 60.4% (52.5–68.0) using MDA, DAPSA-LDA and DAS28, respectively. Conclusion REM/LDA status was reported in only1/3 of recent studies on PsA, with important variations in the frequency of these outcomes according to the definition used: 13.1–42.1% for REM, and 36.3–60.4% for LDA. This highlights the need for consensus.

Sign in / Sign up

Export Citation Format

Share Document